IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 146,659 shares of the company's stock after selling 1,910 shares during the period. IDEXX Laboratories makes up approximately 1.1% of TimesSquare Capital Management LLC's holdings, making the stock its 26th biggest position. TimesSquare Capital Management LLC owned 0.18% of IDEXX Laboratories worth $74,095,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Crewe Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the 1st quarter worth about $26,000. Ridgewood Investments LLC acquired a new position in IDEXX Laboratories during the second quarter valued at approximately $27,000. Institutional & Family Asset Management LLC acquired a new position in IDEXX Laboratories during the second quarter valued at approximately $28,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after buying an additional 57 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock valued at $34,000 after buying an additional 60 shares during the period. 87.84% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IDXX has been the subject of several recent research reports. BTIG Research initiated coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a "buy" rating and a $580.00 target price for the company. Piper Sandler reissued a "neutral" rating and issued a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. JPMorgan Chase & Co. lowered their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research note on Thursday, October 10th. Finally, Barclays reduced their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $552.38.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded up $0.28 during trading on Friday, hitting $433.28. 655,728 shares of the company's stock traded hands, compared to its average volume of 769,371. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 1 year low of $404.74 and a 1 year high of $583.39. The stock has a market capitalization of $35.48 billion, a P/E ratio of 41.78, a PEG ratio of 3.70 and a beta of 1.36. The business has a 50-day simple moving average of $472.83 and a 200-day simple moving average of $485.13.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.53 earnings per share. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.